The same dose (0.5-mL) for all your recommended patients (aged 6 months and older)."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1,"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"2

Rely on one prefilled syringe (PFS) of FLUARIX QUADRIVALENT to cover all recommended ages."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1,"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"4

  Age 6 months through 8 years Age 9 years and older

Vaccination
Status
Not previously vaccinated with influenza vaccine Vaccinated with influenza vaccine in
a previous season
Not applicable

Dose and
Schedule
Two doses (0.5-mL each) at least
4 weeks apart
One or 2 dosesa
(0.5-mL each)
One 0.5-mL dose

  • aOne dose or 2 doses (0.5-mL each) depending on vaccination history as per the annual Advisory Committee on Immunization Practices (ACIP) recommendation on prevention and control of influenza with vaccines. If 2 doses, administer each 0.5-mL dose at least 4 weeks apart.
Administering
FLUARIX QUADRIVALENT
Storing
FLUARIX QUADRIVALENT
Key facts about vaccination errors
With FLUARIX QUADRIVALENT,
you can vaccinate all recommended
patients (6 months +) with the same
dose
(0.5-mL)"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1,"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"2

Please note that there are no data demonstrating that the use of FLUARIX QUADRIVALENT reduces administration errors.

†Reported years 2000-2013. N (total errors reported)=21,843.
‡Institute for Safe Medication Practices National Vaccine Errors Reporting Program.

INDICATION

FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons aged 6 months and older.

Important Safety Information for FLUARIX QUADRIVALENT

  • Do not administer FLUARIX QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLUARIX QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common systemic adverse reactions were muscle aches, headache, and fatigue. In children 6 through 35 months of age, the most common solicited local adverse reactions were pain and redness and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children 3 through 17 years of age, the solicited local adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients

Please see full Prescribing Information for FLUARIX QUADRIVALENT.

View all references.

 

All trademarks are the property of their respective owners.

1007203R0 July 2018